Locally Advanced Cutaneous Squamous Cell Carcinoma (DBCOND0133965)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cemiplimab	A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.	Programmed cell death protein 1target
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04305795	An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors	Cemiplimab Cetuximab sarotalocan Pembrolizumab	treatment	1 / 2	active_not_recruiting
NCT06418724	Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma	Cemiplimab Cetuximab	treatment	2	not_yet_recruiting
NCT05574101	A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer	Cemiplimab	treatment	2	recruiting